Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, CRBP, ACLX, PCVX, LBPH, and represent 40.89% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: RAPP (+$68M), AXSM (+$32M), PCVX (+$31M), ALMS (+$29M), URGN (+$28M), SRPT (+$20M), CGEM (+$20M), YMAB (+$18M), RNA (+$17M), NAMS (+$15M).
- Started 10 new stock positions in IBRX, RAPP, AXSM, RNA, ALMS, URGN, SRPT, YMAB, CGEM, SIGA.
- Reduced shares in these 10 stocks: Alpine Immune Sciences (-$107M), TARS (-$45M), AUTL (-$42M), ALXO (-$35M), BBIO (-$34M), AVTE (-$32M), MRNS (-$29M), TRML (-$29M), PRAX (-$26M), APLS (-$24M).
- Sold out of its positions in ALXO, SYRE, AVTE, Alpine Immune Sciences, APLS, ATXS, AUTL, BEAM, BCAB, CABA. IRON, IMRX, KYTX, MRNS, NKTX, RCKT, TRML, VTYX.
- Cormorant Asset Management was a net seller of stock by $-238M.
- Cormorant Asset Management has $1.7B in assets under management (AUM), dropping by -24.06%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 49 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 21.6 | $374M | 8.5M | 43.97 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 5.3 | $92M | 2.0M | 45.25 |
|
|
| Arcellx Common Stock (ACLX) | 4.9 | $84M | -14% | 1.5M | 55.19 |
|
| Vaxcyte (PCVX) | 4.8 | $83M | +60% | 1.1M | 75.51 |
|
| Longboard Pharmaceuticals In (LBPH) | 4.4 | $75M | -16% | 2.8M | 27.03 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 4.2 | $72M | +20% | 8.3M | 8.70 |
|
| Rapport Therapeutics (RAPP) | 4.0 | $68M | NEW | 2.9M | 23.26 |
|
| Crinetics Pharmaceuticals In (CRNX) | 3.5 | $61M | +17% | 1.4M | 44.79 |
|
| Edgewise Therapeutics (EWTX) | 3.1 | $54M | 3.0M | 18.01 |
|
|
| Merus N V (MRUS) | 2.9 | $50M | +17% | 840k | 59.17 |
|
| Bridgebio Pharma (BBIO) | 2.7 | $47M | -41% | 1.9M | 25.33 |
|
| Insmed Com Par $.01 (INSM) | 2.6 | $45M | +17% | 675k | 67.00 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 2.6 | $44M | +53% | 2.3M | 19.21 |
|
| Janux Therapeutics (JANX) | 2.5 | $44M | +40% | 1.1M | 41.89 |
|
| Axsome Therapeutics (AXSM) | 1.9 | $32M | NEW | 400k | 80.50 |
|
| Cg Oncology (CGON) | 1.8 | $31M | +21% | 975k | 31.57 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.7 | $30M | 2.9M | 10.22 |
|
|
| Alumis (ALMS) | 1.6 | $29M | NEW | 2.1M | 13.30 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.6 | $28M | -47% | 685k | 41.36 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.6 | $28M | 2.1M | 13.22 |
|
|
| Biohaven (BHVN) | 1.6 | $28M | +29% | 802k | 34.71 |
|
| Urogen Pharma (URGN) | 1.6 | $28M | NEW | 1.7M | 16.78 |
|
| Pharvaris N V (PHVS) | 1.6 | $28M | -14% | 1.5M | 18.80 |
|
| Arcutis Biotherapeutics (ARQT) | 1.4 | $24M | +18% | 2.5M | 9.30 |
|
| Sarepta Therapeutics (SRPT) | 1.1 | $20M | NEW | 125k | 158.00 |
|
| Cullinan Oncology (CGEM) | 1.1 | $20M | NEW | 1.1M | 17.44 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.1 | $20M | -13% | 475k | 41.06 |
|
| Cargo Therapeutics (CRGX) | 1.1 | $19M | 1.2M | 16.42 |
|
|
| Y Mabs Therapeutics (YMAB) | 1.0 | $18M | NEW | 1.5M | 12.08 |
|
| Avidity Biosciences Ord (RNA) | 1.0 | $17M | NEW | 425k | 40.85 |
|
| Biomea Fusion (BMEA) | 0.9 | $16M | 3.6M | 4.50 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.8 | $15M | +186% | 1.6M | 9.03 |
|
| Tarsus Pharmaceuticals (TARS) | 0.8 | $14M | -76% | 500k | 27.18 |
|
| Silence Therapeutics Ads (SLN) | 0.7 | $12M | 625k | 19.00 |
|
|
| Arrivent Biopharma (AVBP) | 0.6 | $9.6M | 515k | 18.55 |
|
|
| Engene Holdings (ENGN) | 0.5 | $9.4M | 1.0M | 9.43 |
|
|
| Korro Bio (KRRO) | 0.5 | $9.0M | -49% | 266k | 33.87 |
|
| Ideaya Biosciences (IDYA) | 0.5 | $8.6M | -45% | 245k | 35.11 |
|
| Immunitybio Put Option (IBRX) | 0.5 | $7.9M | NEW | 1.3M | 6.32 |
|
| Gh Research Ordinary Shares (GHRS) | 0.4 | $6.9M | 593k | 11.66 |
|
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.3 | $6.0M | 75k | 80.29 |
|
|
| Stoke Therapeutics (STOK) | 0.3 | $5.8M | 427k | 13.51 |
|
|
| Mersana Therapeutics (MRSN) | 0.3 | $5.2M | 2.6M | 2.01 |
|
|
| Neurogene (NGNE) | 0.2 | $3.9M | -80% | 107k | 36.39 |
|
| SIGA Technologies Put Option (SIGA) | 0.2 | $3.8M | NEW | 500k | 7.59 |
|
| Vyne Therapeutics (VYNE) | 0.2 | $2.7M | 1.4M | 1.97 |
|
|
| Compass Therapeutics (CMPX) | 0.1 | $2.0M | -63% | 2.0M | 1.00 |
|
| Verve Therapeutics (VERV) | 0.1 | $1.7M | 350k | 4.88 |
|
|
| Rapt Therapeutics (RAPT) | 0.1 | $1.5M | 497k | 3.05 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2024 Q2 filed Aug. 14, 2024
- Cormorant Asset Management 2024 Q1 filed May 15, 2024
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022
- Cormorant Asset Management 2022 Q2 filed Aug. 15, 2022
- Cormorant Asset Management 2022 Q1 filed May 16, 2022
- Cormorant Asset Management 2021 Q4 filed Feb. 14, 2022
- Cormorant Asset Management 2021 Q3 filed Nov. 15, 2021
- Cormorant Asset Management 2021 Q2 filed Aug. 16, 2021
- Cormorant Asset Management 2021 Q1 filed May 17, 2021
- Cormorant Asset Management 2020 Q4 filed Feb. 16, 2021
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020